Stephen W. Webster - 08 Jun 2026 Form 4 Insider Report for Eloxx Pharmaceuticals, Inc. (ELOX)

Reporting relationship: Director
Issuer ticker: ELOX
Reported as of: 08 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Jun 2026, 20:00:59 UTC
Prior SEC filing: 01 Jun 2026
Next SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Sumit Aggarwal, Attorney-in-Fact

Key filing fact

Stephen W. Webster filed Form 4 for Eloxx Pharmaceuticals, Inc. (ELOX) on 10 Jun 2026.

Key facts

This page summarizes Stephen W. Webster's Form 4 filing for Eloxx Pharmaceuticals, Inc. (ELOX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2026, 20:00.

Change

Previous filing in this sequence was filed on 01 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001438421 Primary reporting owner

Webster Stephen W

Relationship: Director
Address: C/O ELOXX PHARMACEUTICALS, INC., P.O. BOX 274, ARLINGTON
Signature: /s/ Sumit Aggarwal, Attorney-in-Fact
Signature date: 10 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELOX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +13,587
Change %
Price: $0.000000^*
Shares after: 13,587
Date: 08 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,587
Exercise price: $11.00
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option will vest in 24 substantially equal monthly installments so that the option will be fully vested and exercisable on the second anniversary of the grant date, subject to the Reporting Person's continuous service to the Issuer through the applicable vesting date.